363 related articles for article (PubMed ID: 25319274)
1. Role of interleukin-6 in cachexia: therapeutic implications.
Narsale AA; Carson JA
Curr Opin Support Palliat Care; 2014 Dec; 8(4):321-7. PubMed ID: 25319274
[TBL] [Abstract][Full Text] [Related]
2. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
3. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
4. Exercise as an anti-inflammatory therapy for cancer cachexia: a focus on interleukin-6 regulation.
Daou HN
Am J Physiol Regul Integr Comp Physiol; 2020 Feb; 318(2):R296-R310. PubMed ID: 31823669
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Chacon-Cabrera A; Fermoselle C; Urtreger AJ; Mateu-Jimenez M; Diament MJ; de Kier Joffé ED; Sandri M; Barreiro E
J Cell Physiol; 2014 Nov; 229(11):1660-72. PubMed ID: 24615622
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
8. Curcumin and Resveratrol Improve Muscle Function and Structure through Attenuation of Proteolytic Markers in Experimental Cancer-Induced Cachexia.
Penedo-Vázquez A; Duran X; Mateu J; López-Postigo A; Barreiro E
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443492
[TBL] [Abstract][Full Text] [Related]
9. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
10. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
11. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL-6/STAT3/FoxO signaling pathway.
Wang Y; Sun X; Yang Q; Guo C
Phytother Res; 2023 Aug; 37(8):3380-3393. PubMed ID: 37073890
[TBL] [Abstract][Full Text] [Related]
13. Cachectic skeletal muscle response to a novel bout of low-frequency stimulation.
Puppa MJ; Murphy EA; Fayad R; Hand GA; Carson JA
J Appl Physiol (1985); 2014 Apr; 116(8):1078-87. PubMed ID: 24610533
[TBL] [Abstract][Full Text] [Related]
14. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
15. Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia.
Op den Kamp CM; Langen RC; Snepvangers FJ; de Theije CC; Schellekens JM; Laugs F; Dingemans AM; Schols AM
Am J Clin Nutr; 2013 Sep; 98(3):738-48. PubMed ID: 23902785
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
17. IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia.
Eskiler GG; Bezdegumeli E; Ozman Z; Ozkan AD; Bilir C; Kucukakca BN; Ince MN; Men AY; Aktas O; Horoz YE; Akpinar D; Genc I; Kaleli S
Bratisl Lek Listy; 2019; 66(11):819-826. PubMed ID: 31747761
[TBL] [Abstract][Full Text] [Related]
18. Babao Dan Alleviates Cancer Cachexia in Mice Via Inhibiting IL-6/STAT3 Signaling Pathway.
Qiu Z; Wo D; Zhong X; Chen J; Ma E; He J; Peng J; Zhu W; Ren DN
Integr Cancer Ther; 2023; 22():15347354231168369. PubMed ID: 37077153
[TBL] [Abstract][Full Text] [Related]
19. Short-term pyrrolidine dithiocarbamate administration attenuates cachexia-induced alterations to muscle and liver in ApcMin/+ mice.
Narsale AA; Puppa MJ; Hardee JP; VanderVeen BN; Enos RT; Murphy EA; Carson JA
Oncotarget; 2016 Sep; 7(37):59482-59502. PubMed ID: 27449092
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of sarcopenia and cachexia: recent research advances.
Sakuma K; Aoi W; Yamaguchi A
Pflugers Arch; 2017 Jun; 469(5-6):573-591. PubMed ID: 28101649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
